Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Patient Testimonials In Web Ads Continue To Be Target Of FDA Warning Letters

This article was originally published in The Pink Sheet Daily

Executive Summary

Citation of video for J&J’s Ultram ER is reminiscent of letter to Shire for Adderall XR sent last fall.

You may also be interested in...



Testimonials Lead To Overbroad Claims, DDMAC Warning Letter Says

Implied efficacy claims from a physician and patients for Testopel testosterone pellets, among many other problems with a series of promotional pieces, draw a warning letter to Slate Pharmaceuticals.

Testimonials Lead To Overbroad Claims, DDMAC Warning Letter Says

Implied efficacy claims from a physician and patients for Testopel testosterone pellets, among many other problems with a series of promotional pieces, draw a warning letter to Slate Pharmaceuticals.

FDA Chief Hamburg Says Rx Ads Need Broader Disease Information

New commissioner notes FDA has limited authority in an overloaded media landscape as drug advertising again becomes a target on Capitol Hill.

Related Content

Topics

UsernamePublicRestriction

Register

ID1132542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel